VICTRELIS
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
May 2011
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VICTRELIS is an oral capsule product approved by Merck & Co. in May 2011. The specific indication and mechanism of action are not disclosed in available data. This is a small molecule NDA product.
LOE Approaching1.3 years to LOE
Approaching loss of exclusivity with 1.3 years remaining; brand team likely in transition planning or size optimization mode.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects
Started Oct 2011
32 enrolled
Healthy
Why This Matters for Your Career
Worked on VICTRELIS at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.